Information Provided By: 
Fly News Breaks for December 6, 2019
MGTA
Dec 6, 2019 | 05:03 EDT
Goldman Sachs analyst Paul Choi assumed coverage of Magenta Therapeutics with a Neutral rating with a price target of $18, up from $16. . While encouraged by Magenta's focus on different stages in the transplant process and the curative potential of transplant, the analyst awaits further clinical validation given the mostly early stage nature of its assets.
News For MGTA From the Last 2 Days
There are no results for your query MGTA
